# The Use of DIOVAN to Reduce Post-Cardioversion Recurrence of Atrial Fibrillation Trial (the DRAFT Trial)

> **NCT00343499** · PHASE4 · TERMINATED · sponsor: **Intermountain Health Care, Inc.** · enrollment: 200 (estimated)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** valsartan

## Key facts

- **NCT ID:** NCT00343499
- **Lead sponsor:** Intermountain Health Care, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-11
- **Primary completion:** —
- **Final completion:** 2007-07
- **Target enrollment:** 200 (ESTIMATED)
- **Why stopped:** Inability to recruit
- **Last updated:** 2008-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00343499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00343499, "The Use of DIOVAN to Reduce Post-Cardioversion Recurrence of Atrial Fibrillation Trial (the DRAFT Trial)". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT00343499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*